Suven Life Sciences reappoints Director, approves preferential allotment

Suven Life Sciences Ltd announced board approval for the re-appointment of Dr. Vajja Sambasiva Rao as Non-Executive Independent Director for a second five-year term starting January 21, 2027. The board also approved the preferential allotment of 1,85,70,133 equity shares at ₹134 per share upon conversion of warrants, raising ₹248.84 crore. This issuance increases the company's paid-up equity share capital. Additionally, the company is incorporating a wholly-owned subsidiary in Singapore. The board meeting concluded on July 8, 2026.